Drugs / SKL24741
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04505397 | Feb 2020 → Oct 2022 | — | SK Life Science, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SKL24741 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04505397 ↗ |
| Action | Inhibit | “An inhibitor of voltage-gated sodium channels” NCT04505397 ↗ |
| Route | Oral | “Administered as an oral dose in the form of a capsule or tablet” NCT04505397 ↗ |